Rentschler Biopharma honored as Winner at the 2025 CDMO Leadership Awards  

• Rentschler Biopharma honored as Winner in the Biologics/Global category  
• Award recognizes Rentschler Biopharma’s excellence and leadership in biologics manufacturing and highlights its client-centric approach 

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, has been honored as a winner of the in the Biologics/Global category at the CDMO Leadership Awards 2025. Rentschler Biopharma was also named a finalist for the Champion Award in the Biologics/Global category as well as in the “Best in Scientfic Expertise” and “Best in Quality Management System” categories underscoring its strong industry position and commitment to client satisfaction. Presented by Life Science Connect and Outsourced Pharma, the CDMO Leadership Awards are based on direct client feedback and highlight Rentschler Biopharma’s unwavering commitment to excellence, innovation, and customer satisfaction. The award was presented during the CDMO Leadership Awards Ceremony and Reception in New York City on March 19, 2025. 

“We are honored to receive the prestigious Winner Award of the 2025 CDMO Leadership Awards,” said Benedikt von Braunmühl, CEO of Rentschler Biopharma. “This award is especially meaningful as it is based on direct client feedback, reflecting the trust and confidence our clients place in us and our services. At Rentschler, we work tirelessly to provide services that continually exceed expectations, and this award affirms the strong partnerships we have built with our clients. Being recognized in the Biologics category is particularly significant, as it aligns clearly with our strategic focus. My sincere thank you also goes out to our employees who, with their dedication to advancing medicine to save lives, have made this honor possible.” 

"This award reflects the ongoing commitment of our entire team to operational excellence,” said Christiane Bardroff, COO of Rentschler Biopharma. “Our investments in Milford and Laupheim are enhancing our development and manufacturing capabilities, improving efficiency, and ensuring we continue to meet the highest industry standards. This allows us to reliably deliver high-quality biopharmaceuticals to our clients and, ultimately, to patients who are in need of cutting-edge, life-saving therapies.” 

In recent years, Rentschler Biopharma has made substantial investments to expand its global capabilities and drive long-term growth. In 2024, the company announced its largest single investment to date at its headquarters in Laupheim, Germany, aimed at enhancing production efficiency and upgrading site capabilities. Earlier that year, its state-of-the-art production line in Milford, MA, U.S., became fully operational, featuring four new 2,000 L single-use bioreactors. This milestone investment further strengthens Rentschler Biopharma’s manufacturing capacity and ability to meet the growing demand for biopharmaceuticals. Earlier this year, the company announced its decision to increase its focus on biologics as part of its strategy to adapt to evolving market conditions and client needs, prioritize sustainable growth, and drive innovation. 

“We are thrilled to introduce our 2025 CDMO Leadership Awards winners to the outsourcing community and honored to offer such an important tool for drug sponsors in selecting their best-fit partner to help bring life-saving therapies to market,” says Outsourced Pharma Chief Editor Louis Garguilo. “The new categories and enhanced scoring methodology that went into effect this year’s appraisal bring an improved experience for drug sponsors using the resource as well as an ever-so-coveted distinction for the CDMOs.” 

The CDMO Leadership Awards, organized by Outsourced Pharma and Life Science Connect, recognize excellence in contract development and manufacturing across key industry segments. In response to feedback from readers and sponsors, the 2025 edition introduces new categories and an enhanced scoring system for a more comprehensive evaluation. The awards now cover Biologics, Cell & Gene Therapy, Small Molecule API, and Small Molecule Dosage Form, with each category divided into Global, North American, and International regions. This year’s scoring methodology is based on input from 289 industry professionals who evaluated 210 CDMOs.